A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
Authors
Keywords
Stage IV melanoma, Immunocytokine, L19IL2, Dacarbazine, Phase II study
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 68, Issue 9, Pages 1547-1559
Publisher
Springer Science and Business Media LLC
Online
2019-09-04
DOI
10.1007/s00262-019-02383-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
- (2019) Cornelia Hutmacher et al. Cancer Immunology Research
- Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains
- (2018) Roberto De Luca et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- Immunocytokines for cancer treatment: past, present and future
- (2016) Dario Neri et al. CURRENT OPINION IN IMMUNOLOGY
- Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma
- (2015) Chun-Feng Wu et al. Asia-Pacific Journal of Clinical Oncology
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
- (2015) Nicolle H. Rekers et al. RADIOTHERAPY AND ONCOLOGY
- The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer
- (2015) Chiara Catania et al. Cell Adhesion & Migration
- Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2015) Christoph Schliemann et al. Cancer Immunology Research
- Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
- (2015) C. M. L. Zegers et al. CLINICAL CANCER RESEARCH
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice
- (2014) K. L. Gutbrodt et al. MOLECULAR CANCER THERAPEUTICS
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
- (2014) B. Weide et al. Cancer Immunology Research
- Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
- (2013) Chelsea Ma et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
- (2013) K. L. Gutbrodt et al. Science Translational Medicine
- Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours
- (2012) G. Spitaleri et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention
- (2012) R. K. Yang et al. JOURNAL OF IMMUNOLOGY
- The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
- (2012) Kathrin Schwager et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
- (2012) P. A. Erba et al. JOURNAL OF NUCLEAR MEDICINE
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions
- (2011) Katharina Frey et al. EXPERIMENTAL DERMATOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
- (2009) S. Sauer et al. BLOOD
- Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
- (2009) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFα
- (2009) Enrica Balza et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
- (2009) Antoni Ribas et al. Journal of Translational Medicine
- Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma
- (2009) Christoph Schliemann et al. LEUKEMIA RESEARCH
- Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
- (2009) Michael B. Atkins MEDICAL ONCOLOGY
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
- (2008) C. Schliemann et al. BLOOD
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
- (2008) F. O. Smith et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now